Press Releases

Date Title and Summary View
Toggle Summary Aquinox Pharmaceuticals Prices Initial Public Offering
VANCOUVER, British Columbia, March 7, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. announced today the pricing of its initial public offering of 4,200,000 shares of its common stock at a public offering price of $11.00 per share for an aggregate offering of $46.2 million, before
View HTML
Toggle Summary Aquinox Pharmaceuticals commences Phase 2 clinical trial of AQX-1125 in Chronic Obstructive Pulmonary Disease
Oral once daily therapy being studied for population of highest unmet need and leading cause of urgent hospitalizations
View HTML
Toggle Summary Aquinox Pharmaceuticals commences Phase II clinical trial of AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis
Once a day oral therapy being studied for condition that predominantly affects women and has major health consequences
View HTML
Toggle Summary Aquinox Pharmaceuticals Completes US $18 Million Series C Financing
Positive Phase IIa results attract additional funds and new syndicate member to advance clinical development and strengthen management team
View HTML
Toggle Summary Aquinox Pharmaceuticals Initiates Two Phase IIa Clinical Studies in Airway Inflammation Following Successful Phase I
AQX-1125, a novel oral anti-Inflammatory compound, exhibits desirable properties for continued development
View HTML
Toggle Summary Aquinox Pharmaceuticals Receives Regulatory Clearance to Initiate First Clinical Study of AQX-1125, A Novel Oral Anti-Inflammatory Compound
Aquinox Pharmaceuticals Receives Regulatory Clearance to Initiate First Clinical Study of AQX-1125, A Novel Oral Anti-Inflammatory Compound Vancouver, British Columbia - January 5, 2011 Aquinox Pharmaceuticals Inc., a private, venture-backed, biopharmaceutical company developing novel and targeted
View HTML
Toggle Summary Aquinox Pharmaceuticals appoints Csaba Szabó, M.D., Ph.D., Vice President, Research and Chief Scientific Officer
Renowned pharmacologist joins world-leading research and development effort
View HTML
Toggle Summary Aquinox Pharmaceuticals Completes US $25 Million Series B Financing
New Investor - Pfizer Venture Investments - Joins Syndicate
View HTML
Toggle Summary Aquinox Pharmaceuticals Selects AQX-1125 as Lead Clinical Candidate
Aquinox Pharmaceuticals Selects AQX-1125 as Lead Clinical Candidate Vancouver, Canada and London, UK - October 11, 2009 Aquinox Pharmaceuticals Inc., a private, venture-backed, biopharmaceutical company developing novel and targeted small molecule therapeutics for the treatment of inflammatory
View HTML
Toggle Summary Aquinox Pharmaceuticals Inc. Names Board Member
Aquinox Pharmaceuticals Inc. Names Board Member Vancouver, British Columbia - July 10, 2008 Aquinox Pharmaceuticals is pleased to announce the addition of Dr. Daniel Levitt as an independent member of the Board of Directors. Dr. Levitt joined Cerimon Pharmaceuticals Inc.
View HTML